Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05113745 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)
A Phase 3 study, sponsored by Axsome Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 68
- Enrollment target
NCT05113745 is a Phase 3 study that has completed, run by Axsome Therapeutics. The registered enrollment target is 68 participants.
The verdict
NCT05113745, a Phase 3 study, has completed, sponsored by Axsome Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 68 participants
- Enrollment target
Study Summary
This study will evaluate the long-term efficacy and safety of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).
Interventions
- DRUG Placebo
- DRUG AXS-12 (reboxetine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2021-10-20 |
| Est. Completion | 2024-11-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05113745
The ClinicalTrials.gov registry entry for NCT05113745 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axsome Therapeutics, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05113745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05113745 about?
NCT05113745 is a clinical study titled "A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)". This study will evaluate the long-term efficacy and safety of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).
What is the current status of trial NCT05113745?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 68 participants. The study started on 2021-10-20. Estimated completion is 2024-11-15.
What interventions are being tested in trial NCT05113745?
The interventions under investigation include: Placebo (DRUG), AXS-12 (reboxetine) (DRUG).
Who is sponsoring clinical trial NCT05113745?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.